Abstract
As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterised as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death. NAFLD is also associated with extrahepatic manifestations such as chronic kidney disease, cardiovascular disease and sleep apnoea. NAFLD and NASH carry a large economic burden and create poor health-related quality of life. Despite this important burden, we are only beginning to understand its mechanisms of pathogenesis and the contribution of environmental and genetic factors to the risk of developing a progressive course of disease. Research is underway to identify appropriate non-invasive diagnostic methods and effective treatments. Although the risk of liver-related mortality is increased in patients with NAFLD and liver fibrosis stages F3 or F4, the leading cause of death is cardiovascular disease. Given the rapidly growing global burden of NAFLD and NASH, efforts must continue to find accurate non-invasive diagnostic and prognostic biomarkers, to develop effective treatments for individuals with advanced NASH and prevention methods for individuals at high risk of NAFLD and progressive liver disease.
Keywords
MedicineFatty liverSteatohepatitisCirrhosisDiseaseLiver transplantationLiver diseaseHepatocellular carcinomaInternal medicineAlcoholic liver diseaseIntensive care medicineGastroenterologyTransplantation
MeSH Terms
CausalityForecastingGlobal HealthHumansNon-alcoholic Fatty Liver DiseasePublic Health
Affiliated Institutions
Related Publications
Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults
Aliment Pharmacol Ther 2011; 34: 274–285 Summary Background Non‐alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, and its worldwide prevalence co...
Nonalcoholic Steatohepatitis
Nonalcoholic fatty liver disease (NAFLD) is being increasingly recognized as a common liver disorder that represents the hepatic manifestation of the metabolic syndrome, a varia...
Non‐alcoholic fatty liver disease: An overview
Abstract Non‐alcoholic fatty liver disease (NAFL) includes a spectrum of clinicopathological conditions with increasing prevalence in the developed world. Although steatosis alo...
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide. We estimated the global prevalence, incidence, progression, and outcomes of NAFLD and nonal...
Non‐alcoholic steatohepatitis: Definitions and pathogenesis
The term 'non-alcoholic steatohepatitis' or NASH was first used by Ludwig et al. in 1980 to describe 'the pathological and clinical features of non-alcoholic disease of the live...
Publication Info
- Year
- 2018
- Type
- review
- Volume
- 70
- Issue
- 3
- Pages
- 531-544
- Citations
- 2044
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
2044
OpenAlex
51
Influential
1763
CrossRef
Cite This
Zobair M. Younossi
(2018).
Non-alcoholic fatty liver disease – A global public health perspective.
Journal of Hepatology
, 70
(3)
, 531-544.
https://doi.org/10.1016/j.jhep.2018.10.033
Identifiers
- DOI
- 10.1016/j.jhep.2018.10.033
- PMID
- 30414863